首页> 美国卫生研究院文献>Diabetes Metabolism Journal >Anti-Obesity Drugs: A Review about Their Effects and Safety
【2h】

Anti-Obesity Drugs: A Review about Their Effects and Safety

机译:抗肥胖药:其作用和安全性综述

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The current recommendations for the treatment of obese people include increased physical activity and reduced calories intake. When the behavioral approach is not sufficient, a pharmacologic treatment is recommended. In past years, numerous drugs have been approved for the treatment of obesity; however, most of them have been withdrawn from the market because of their adverse effects. In fact, amphetamine, rimonabant and sibutramine licenses have been withdrawn due to an increased risk of psychiatric disorders and non-fatal myocardial infarction or stroke. Even if orlistat is not as effective as other drugs in reducing body weight, orlistat is presently the only available choice for the treatment of obesity because of its safety for cardiovascular events and positive effects on diabetic control. Hopefully, more effective and better tolerated anti-obesity drugs will be developed through an improved understanding of the multiple mechanisms and complex physiological systems targeting appetite.
机译:当前对肥胖者的治疗建议包括增加体育锻炼和减少卡路里摄入。当行为方法不足时,建议进行药物治疗。在过去的几年中,许多药物被批准用于治疗肥胖症。然而,由于它们的不利影响,大多数已退出市场。实际上,由于精神疾病和非致命性心肌梗塞或中风的风险增加,苯丙胺,利莫那班和西布曲明的许可证已被撤销。即使奥利司他在减轻体重方面不如其他药物有效,但奥利司他由于其对心血管事件的安全性和对糖尿病控制的积极作用,目前仍是肥胖症治疗的唯一可用选择。希望通过更好地了解针对食欲的多种机制和复杂的生理系统,开发出更有效,耐受性更好的抗肥胖药。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号